Verekitug Phase 2 Data Show 80% Responder Rate in Nasal Polyp Trial
The EAACI 2026 responder analysis adds to mounting evidence for targeted biologics in upper-airway inflammatory conditi…
The EAACI 2026 responder analysis adds to mounting evidence for targeted biologics in upper-airway inflammatory conditi…
The coalition push highlights growing intersections between blood health, iron status nutrition, and functional supplem…
The submitted release covers hospital AI strategy, not functional ingredients, nutraceuticals, or dietary supplements —…
Submission appears to be a healthcare AI conference announcement unrelated to functional foods, ingredients, or nutriti…
Submission flagged as out-of-scope. Functional News covers ingredients, formulations, clinical trials, and regulatory n…
Functional News covers functional foods, dietary supplements, nutraceuticals, and evidence-based ingredients. This rele…
Submitted release covers hospital AI governance at a European health-tech conference — outside Functional News editoria…
Pyruvate kinase activation as a therapeutic mechanism draws renewed attention as clinical-stage data surfaces at a majo…
Six-month interim results reinforce MC4R pathway as a viable therapeutic target, with Phase 3 development now in the ra…
The MC4R-pathway agonist is under scrutiny as a potential model for appetite-regulating therapeutics at the rare-diseas…
Editorial note: submission reviewed and declined. No ingredient, mechanism, clinical endpoint, or regulatory hook appli…
As clean-label beauty-from-outside converges with nutricosmetics, topical actives targeting neck laxity signal a formul…